Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)

Devaki Shilpa Surasi(The University of Texas MD Anderson Cancer Center), Morand Piert, Ian Cox(The University of Texas MD Anderson Cancer Center), Mary A. Lokuta, Phillip H. Kuo, Michael L. Cher(Wayne State University), Michael N. Ferrandino, Shreyas Joshi, David Gauden(Emory University), Isuru Jayaratna, William C. Lavely, Bridget F. Koontz(Duke University), Mohamad E. Allaf, Benjamin A. Gartrell, Benjamin Lowentritt, Peter Gardiner(University of Turku), Norbert Avril, Lale Kostakoğlu, Tobias Maurer(Universität Hamburg), Ergela Hasa, R. H. C. Penny, Thomas Horn, David M. Schuster(Emory University), Diederik M. Somford(Canisius-Wilhelmina Ziekenhuis), Soroush Rais‐Bahrami(University of Alabama at Birmingham), Heather A. Jacene(Moffitt Cancer Center), Dinko Franceschi, Kenneth Ogan, Ashutosh Tewari(Mount Sinai Hospital), Pooya Iranpour, Lars Budäus, Jeffrey W. Nix, Mark T. Fleming(Virginia Oncology Associates), Brian F. Chapin(The University of Texas MD Anderson Cancer Center), Matthew F. Covington, Gerald L. Andriole(Washington University in St. Louis), Peter J. Boström(University of Turku), Ryan Avery, Phillip Davis, Matthew P. Miller, Matthew D. Kay, Matthias Eiber(TUM Klinikum), Mark A. Preston(Brigham and Women's Hospital), Brian T. Helfand(NorthShore University HealthSystem), Rick Hermsen, Helen Barker, David Josephson(Cedars-Sinai Medical Center), Albert Chau(Blue Earth Diagnostics (United Kingdom)), Diane Chisholm, Laurence Belkoff
European Urology
July 5, 2023
Cited by 90


Related Papers